10/31/14 ANAC 29.41 Anacor Pharmaceuticals $ANAC H
Post# of 102
Posted On: 11/01/2014 10:42:18 PM
10/31/14 ANAC 29.41 Anacor Pharmaceuticals $ANAC Hit a 52 week high of 31.78 Closing the day 10/31/14 at 29.41 -0.67 -2.23% With a day low of 29.40 and a total volume of 914,700.
ANAC Recent Posts: http://investorshangout.com/Anacor-Pharmaceut...NAC-53325/
ANAC Anacor Pharmaceuticals Recent Headline News
Anacor Pharmaceuticals Announces Third Quarter 2014 Financial Results Conference Call and Webcast
Business Wire - Thu Oct 30, 3:30PM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) will release its financial results for the third quarter ended September 30, 2014, on Thursday, November 6, 2014 at approximately 4:00 p.m. ET / 1:00 p.m. PT. The announcement will be followed by a conference call at 5:00 p.m. ET / 2:00 p.m. PT during which management will discuss the company's financial results and recent developments. The call may be accessed by dialing (877) 291-1367 (domestic) and (914) 495-8534 (international) five minutes prior to the start of the call. The call will also be webcast live and may be accessed on the Events and Presentations page, under Investors, on the company's website at www.anacor.com where it will be available for three months following the call.
ANAC: 29.41 (-0.67)
Strong On High Relative Volume: Anacor Pharmaceuticals (ANAC)
at The Street - Mon Oct 20, 9:05AM CDT
Trade-Ideas LLC identified Anacor Pharmaceuticals (ANAC) as a strong on high relative volume candidate
ANAC: 29.41 (-0.67)
3 Stocks Spiking on Unusual Volume
at The Street - Mon Oct 13, 6:22AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
IPXL: 28.97 (+0.35), ANAC: 29.41 (-0.67), MSTR: 160.88 (+0.88)
Anacor Pharmaceuticals prices offering of USD75m convertible senior notes
M2 - Fri Oct 10, 6:57AM CDT
Biopharmaceutical company Anacor Pharmaceuticals (NasdaqGM:ANAC) said on Thursday that it has priced its offering of USD75m aggregate principal amount of 2.00% convertible senior notes due 2021 in a private placement.
ANAC: 29.41 (-0.67)
Anacor Pharmaceuticals, Inc. Announces Pricing of Offering of $75 Million of 2.00% Convertible Senior Notes Due 2021
Business Wire - Thu Oct 09, 6:29PM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today the pricing of its offering of $75,000,000 aggregate principal amount of 2.00% Convertible Senior Notes due 2021 (the "Convertible Notes"
in a private placement under the Securities Act of 1933, as amended (the "Securities Act" . Anacor also granted the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $7,500,000 aggregate principal amount of the Convertible Notes, solely to cover over-allotments, if any. In addition, certain funds affiliated with Venrock Associates, one of Anacor's affiliates, have agreed to purchase $8.0 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Venrock Notes" in a concurrent private placement under the Securities Act. The Venrock Notes will be sold at the same price, and will constitute part of the same series, as the Convertible Notes. The offering of the Convertible Notes is expected to close on October 16, 2014, subject to customary closing conditions. The sale of the Venrock Notes is also expected to close on October 16, 2014, subject to the closing of the Convertible Notes offering.
ANAC: 29.41 (-0.67)
Anacor Pharmaceuticals, Inc. Announces Proposed Offering of $70 Million of Convertible Senior Notes Due 2021
Business Wire - Wed Oct 08, 3:01PM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that it intends to offer, subject to market and other considerations, $70,000,000 aggregate principal amount of Convertible Senior Notes due 2021 (the "Convertible Notes" in a private placement under the Securities Act of 1933, as amended (the "Securities Act" . Anacor also intends to grant to the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $7,000,000 aggregate principal amount of the Convertible Notes, solely to cover over-allotments, if any. In addition, certain funds affiliated with Venrock Associates (the "Venrock Funds" , one of Anacor's affiliates, have indicated an interest in purchasing $12.0 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Venrock Notes" in a concurrent private placement under the Securities Act. The Venrock Notes are expected to be sold at the same price, and constitute part of the same series, as the Convertible Notes. The Venrock Funds' indication of interest is not a binding agreement or commitment to purchase the Venrock Notes.
ANAC: 29.41 (-0.67)
Insider Trading Alert - NDAQ, ANAC And RNR Traded By Insiders
at The Street - Fri Oct 03, 10:15AM CDT
Stocks with insider trader activity include NDAQ, ANAC and RNR
RNR: 103.33 (+0.65), ANAC: 29.41 (-0.67), NDAQ: 43.26 (+0.49)
Anacor's Kerydin Launched in the US for Onychomycosis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 4:05PM CDT
Anacor Pharmaceuticals, Inc.'s (ANAC) Kerydin has been launched in the U.S. by partner Sandoz Inc., a Novartis company.
ANAC: 29.41 (-0.67), SNY: 46.24 (+0.54), REGN: 393.72 (+0.92), NVS: 92.69 (+0.74)
Anacor Pharmaceuticals unveils antifungal drug KERYDIN (tavaborole) Topical Solution, 5% in the US
M2 - Tue Sep 23, 4:47AM CDT
Biopharmaceutical company Anacor Pharmaceuticals (NasdaqGM:ANAC) Monday reported the US launch of its US Food and Drug Administration approved drug KERYDINTM (tavaborole) topical solution, 5%.
ANAC: 29.41 (-0.67)
Anacor Pharmaceuticals Announces Commercial Launch of KERYDIN (tavaborole) Topical Solution, 5% in the United States
Business Wire - Mon Sep 22, 3:05PM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) today announced the U.S. launch of Anacor's FDA-approved drug KERYDIN(TM) (tavaborole) topical solution, 5% by Sandoz Inc., a Novartis company. KERYDIN is the first oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States, according to Podiatry Today. In July 2014, Anacor announced that it had entered into an exclusive agreement with Sandoz, pursuant to which Sandoz will distribute and commercialize KERYDIN in the United States.
ANAC: 29.41 (-0.67)
Merck KGaA-Lupin Ink Deal, Focus on Emerging Markets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 3:14PM CDT
Merck KGaA (MKGAF) entered into a partnership with Lupin Ltd. with the aim of expanding Merck KGaA's General Medicine & Endocrinology franchise in emerging markets.
LCI: 56.72 (+0.83), AVNR: 12.94 (-0.26), ANAC: 29.41 (-0.67)
The Zacks Analyst Blog Highlights: Merck KGaA, Lannett, Avanir Pharmaceuticals, Anacor Pharmaceuticals and Helen of Troy
PR Newswire - Tue Sep 16, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Merck KGaA (OTC:MKGAF-Free Report), Lannett Company, Inc. (NYSE:LCI-Free Report), Avanir Pharmaceuticals, Inc. (Nasdaq:AVNR-Free Report), Anacor Pharmaceuticals, Inc. (Nasdaq:ANAC-Free Report) and Helen of Troy Limited (Nasdaq:HELE-Free Report).
LCI: 56.72 (+0.83), ANAC: 29.41 (-0.67)
Merck KGaA Stops All Tecemotide Studies for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 2:42PM CDT
Merck KGaA (MKGAF) stops all studies on tecemotide as a monotherapy for non-small cell lung cancer (NSCLC) and focuses on developing other candidates.
LCI: 56.72 (+0.83), AVNR: 12.94 (-0.26), ANAC: 29.41 (-0.67)
Anacor Pharmaceuticals Appoints Wendell Wierenga to Its Board of Directors
Business Wire - Fri Sep 12, 7:30AM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that its Board of Directors has appointed Wendell Wierenga, Ph.D. to serve as a Class III director until the Company's 2016 annual meeting of shareholders. Anacor also announced that Paul Klingenstein has resigned from the Board.
CYTK: 3.67 (-0.13), SNTS: (), OCRX: 5.80 (+0.10), ANAC: 29.41 (-0.67), XNPT: 6.78 (-0.13)
Acute Inflammation Therapeutics Pipeline Report 2014 - 9 Companies & 10 Drug Profiles
M2 - Wed Sep 10, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/849tzx/acute) has announced the addition of the "Acute Inflammation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Inflammation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - BioLineRx, Ltd. - Actelion Ltd - Forest Laboratories, Inc. - Italfarmaco S.p.A. - Alligator Bioscience AB - Anacor Pharmaceuticals, Inc. - Omeros Corporation - Dompe Farmaceutici S.p.A. - Peptinnovate Limited Drug Profiles - ACT-389949 - ATL-1222 - CGEN-856 - ADC-1004 - DF-2156A - Selective Inhibitor of Pro Inflammatory Cytokine - AN-3485 - PIN-201104 - Small Molecule Targeting GPR32 for Acute Inflammation - Distamycin Derivatives For more information visit http://www.researchandmarkets.com/research/849tzx/acute
ANAC: 29.41 (-0.67), FRX: 99.00 (-0.77), OMER: 16.57 (unch)
Astellas' Antifungal Under FDA Review, Response by Mar 2015 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:50PM CDT
Astellas (ALPMY) and partner Basilea's new drug application for isavuconazole is under FDA review for invasive aspergillosis and invasive mucormycosis.
LCI: 56.72 (+0.83), ENDP: 66.92 (+0.63), ANAC: 29.41 (-0.67)
Anacor Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
Business Wire - Wed Sep 03, 4:05PM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that Paul Berns, the company's President and Chief Executive Officer, will provide a company overview at the Morgan Stanley Global Healthcare Conference on Tuesday, September 9, 2014 at 3:30 p.m. ET in New York, New York. The event will be webcast live and may be accessed under "Events and Presentations" on the Investors page of Anacor's website at www.anacor.com. A replay will also be available for three months following the presentation.
ANAC: 29.41 (-0.67), MS: 34.95 (+0.43)
Merck KGaA Q2 Earnings Slip Y/Y, 2014 Sales View Confirmed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 15, 8:00AM CDT
Merck KGaA's (MKGAF) second-quarter 2014 earnings per American Depositary Receipt (ADR) came in at $1.52, down 1.8% from the year-ago quarter.
ENDP: 66.92 (+0.63), UTHR: 130.97 (+0.54), ANAC: 29.41 (-0.67)
Rigel's R348 Fails in Phase II Study, Shares Down 13.6% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 2:30PM CDT
Rigel Pharmaceuticals, Inc. (RIGL) R348 failed to meet the primary and secondary endpoints in a phase II study for the treatment of dry eye disease.
ENDP: 66.92 (+0.63), UTHR: 130.97 (+0.54), ANAC: 29.41 (-0.67), RIGL: 1.98 (+0.02)
Anacor (ANAC) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 8:49AM CDT
Anacor (ANAC) Shares March Higher, Can It Continue?
ANAC: 29.41 (-0.67)
ANAC Recent Posts: http://investorshangout.com/Anacor-Pharmaceut...NAC-53325/
ANAC Anacor Pharmaceuticals Recent Headline News
Anacor Pharmaceuticals Announces Third Quarter 2014 Financial Results Conference Call and Webcast
Business Wire - Thu Oct 30, 3:30PM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) will release its financial results for the third quarter ended September 30, 2014, on Thursday, November 6, 2014 at approximately 4:00 p.m. ET / 1:00 p.m. PT. The announcement will be followed by a conference call at 5:00 p.m. ET / 2:00 p.m. PT during which management will discuss the company's financial results and recent developments. The call may be accessed by dialing (877) 291-1367 (domestic) and (914) 495-8534 (international) five minutes prior to the start of the call. The call will also be webcast live and may be accessed on the Events and Presentations page, under Investors, on the company's website at www.anacor.com where it will be available for three months following the call.
ANAC: 29.41 (-0.67)
Strong On High Relative Volume: Anacor Pharmaceuticals (ANAC)
at The Street - Mon Oct 20, 9:05AM CDT
Trade-Ideas LLC identified Anacor Pharmaceuticals (ANAC) as a strong on high relative volume candidate
ANAC: 29.41 (-0.67)
3 Stocks Spiking on Unusual Volume
at The Street - Mon Oct 13, 6:22AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
IPXL: 28.97 (+0.35), ANAC: 29.41 (-0.67), MSTR: 160.88 (+0.88)
Anacor Pharmaceuticals prices offering of USD75m convertible senior notes
M2 - Fri Oct 10, 6:57AM CDT
Biopharmaceutical company Anacor Pharmaceuticals (NasdaqGM:ANAC) said on Thursday that it has priced its offering of USD75m aggregate principal amount of 2.00% convertible senior notes due 2021 in a private placement.
ANAC: 29.41 (-0.67)
Anacor Pharmaceuticals, Inc. Announces Pricing of Offering of $75 Million of 2.00% Convertible Senior Notes Due 2021
Business Wire - Thu Oct 09, 6:29PM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today the pricing of its offering of $75,000,000 aggregate principal amount of 2.00% Convertible Senior Notes due 2021 (the "Convertible Notes"
in a private placement under the Securities Act of 1933, as amended (the "Securities Act" . Anacor also granted the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $7,500,000 aggregate principal amount of the Convertible Notes, solely to cover over-allotments, if any. In addition, certain funds affiliated with Venrock Associates, one of Anacor's affiliates, have agreed to purchase $8.0 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Venrock Notes" in a concurrent private placement under the Securities Act. The Venrock Notes will be sold at the same price, and will constitute part of the same series, as the Convertible Notes. The offering of the Convertible Notes is expected to close on October 16, 2014, subject to customary closing conditions. The sale of the Venrock Notes is also expected to close on October 16, 2014, subject to the closing of the Convertible Notes offering. ANAC: 29.41 (-0.67)
Anacor Pharmaceuticals, Inc. Announces Proposed Offering of $70 Million of Convertible Senior Notes Due 2021
Business Wire - Wed Oct 08, 3:01PM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that it intends to offer, subject to market and other considerations, $70,000,000 aggregate principal amount of Convertible Senior Notes due 2021 (the "Convertible Notes"
in a private placement under the Securities Act of 1933, as amended (the "Securities Act" . Anacor also intends to grant to the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $7,000,000 aggregate principal amount of the Convertible Notes, solely to cover over-allotments, if any. In addition, certain funds affiliated with Venrock Associates (the "Venrock Funds" , one of Anacor's affiliates, have indicated an interest in purchasing $12.0 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Venrock Notes" in a concurrent private placement under the Securities Act. The Venrock Notes are expected to be sold at the same price, and constitute part of the same series, as the Convertible Notes. The Venrock Funds' indication of interest is not a binding agreement or commitment to purchase the Venrock Notes. ANAC: 29.41 (-0.67)
Insider Trading Alert - NDAQ, ANAC And RNR Traded By Insiders
at The Street - Fri Oct 03, 10:15AM CDT
Stocks with insider trader activity include NDAQ, ANAC and RNR
RNR: 103.33 (+0.65), ANAC: 29.41 (-0.67), NDAQ: 43.26 (+0.49)
Anacor's Kerydin Launched in the US for Onychomycosis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 4:05PM CDT
Anacor Pharmaceuticals, Inc.'s (ANAC) Kerydin has been launched in the U.S. by partner Sandoz Inc., a Novartis company.
ANAC: 29.41 (-0.67), SNY: 46.24 (+0.54), REGN: 393.72 (+0.92), NVS: 92.69 (+0.74)
Anacor Pharmaceuticals unveils antifungal drug KERYDIN (tavaborole) Topical Solution, 5% in the US
M2 - Tue Sep 23, 4:47AM CDT
Biopharmaceutical company Anacor Pharmaceuticals (NasdaqGM:ANAC) Monday reported the US launch of its US Food and Drug Administration approved drug KERYDINTM (tavaborole) topical solution, 5%.
ANAC: 29.41 (-0.67)
Anacor Pharmaceuticals Announces Commercial Launch of KERYDIN (tavaborole) Topical Solution, 5% in the United States
Business Wire - Mon Sep 22, 3:05PM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) today announced the U.S. launch of Anacor's FDA-approved drug KERYDIN(TM) (tavaborole) topical solution, 5% by Sandoz Inc., a Novartis company. KERYDIN is the first oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States, according to Podiatry Today. In July 2014, Anacor announced that it had entered into an exclusive agreement with Sandoz, pursuant to which Sandoz will distribute and commercialize KERYDIN in the United States.
ANAC: 29.41 (-0.67)
Merck KGaA-Lupin Ink Deal, Focus on Emerging Markets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 3:14PM CDT
Merck KGaA (MKGAF) entered into a partnership with Lupin Ltd. with the aim of expanding Merck KGaA's General Medicine & Endocrinology franchise in emerging markets.
LCI: 56.72 (+0.83), AVNR: 12.94 (-0.26), ANAC: 29.41 (-0.67)
The Zacks Analyst Blog Highlights: Merck KGaA, Lannett, Avanir Pharmaceuticals, Anacor Pharmaceuticals and Helen of Troy
PR Newswire - Tue Sep 16, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Merck KGaA (OTC:MKGAF-Free Report), Lannett Company, Inc. (NYSE:LCI-Free Report), Avanir Pharmaceuticals, Inc. (Nasdaq:AVNR-Free Report), Anacor Pharmaceuticals, Inc. (Nasdaq:ANAC-Free Report) and Helen of Troy Limited (Nasdaq:HELE-Free Report).
LCI: 56.72 (+0.83), ANAC: 29.41 (-0.67)
Merck KGaA Stops All Tecemotide Studies for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 2:42PM CDT
Merck KGaA (MKGAF) stops all studies on tecemotide as a monotherapy for non-small cell lung cancer (NSCLC) and focuses on developing other candidates.
LCI: 56.72 (+0.83), AVNR: 12.94 (-0.26), ANAC: 29.41 (-0.67)
Anacor Pharmaceuticals Appoints Wendell Wierenga to Its Board of Directors
Business Wire - Fri Sep 12, 7:30AM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that its Board of Directors has appointed Wendell Wierenga, Ph.D. to serve as a Class III director until the Company's 2016 annual meeting of shareholders. Anacor also announced that Paul Klingenstein has resigned from the Board.
CYTK: 3.67 (-0.13), SNTS: (), OCRX: 5.80 (+0.10), ANAC: 29.41 (-0.67), XNPT: 6.78 (-0.13)
Acute Inflammation Therapeutics Pipeline Report 2014 - 9 Companies & 10 Drug Profiles
M2 - Wed Sep 10, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/849tzx/acute) has announced the addition of the "Acute Inflammation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Inflammation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - BioLineRx, Ltd. - Actelion Ltd - Forest Laboratories, Inc. - Italfarmaco S.p.A. - Alligator Bioscience AB - Anacor Pharmaceuticals, Inc. - Omeros Corporation - Dompe Farmaceutici S.p.A. - Peptinnovate Limited Drug Profiles - ACT-389949 - ATL-1222 - CGEN-856 - ADC-1004 - DF-2156A - Selective Inhibitor of Pro Inflammatory Cytokine - AN-3485 - PIN-201104 - Small Molecule Targeting GPR32 for Acute Inflammation - Distamycin Derivatives For more information visit http://www.researchandmarkets.com/research/849tzx/acute
ANAC: 29.41 (-0.67), FRX: 99.00 (-0.77), OMER: 16.57 (unch)
Astellas' Antifungal Under FDA Review, Response by Mar 2015 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:50PM CDT
Astellas (ALPMY) and partner Basilea's new drug application for isavuconazole is under FDA review for invasive aspergillosis and invasive mucormycosis.
LCI: 56.72 (+0.83), ENDP: 66.92 (+0.63), ANAC: 29.41 (-0.67)
Anacor Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
Business Wire - Wed Sep 03, 4:05PM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that Paul Berns, the company's President and Chief Executive Officer, will provide a company overview at the Morgan Stanley Global Healthcare Conference on Tuesday, September 9, 2014 at 3:30 p.m. ET in New York, New York. The event will be webcast live and may be accessed under "Events and Presentations" on the Investors page of Anacor's website at www.anacor.com. A replay will also be available for three months following the presentation.
ANAC: 29.41 (-0.67), MS: 34.95 (+0.43)
Merck KGaA Q2 Earnings Slip Y/Y, 2014 Sales View Confirmed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 15, 8:00AM CDT
Merck KGaA's (MKGAF) second-quarter 2014 earnings per American Depositary Receipt (ADR) came in at $1.52, down 1.8% from the year-ago quarter.
ENDP: 66.92 (+0.63), UTHR: 130.97 (+0.54), ANAC: 29.41 (-0.67)
Rigel's R348 Fails in Phase II Study, Shares Down 13.6% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 2:30PM CDT
Rigel Pharmaceuticals, Inc. (RIGL) R348 failed to meet the primary and secondary endpoints in a phase II study for the treatment of dry eye disease.
ENDP: 66.92 (+0.63), UTHR: 130.97 (+0.54), ANAC: 29.41 (-0.67), RIGL: 1.98 (+0.02)
Anacor (ANAC) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 8:49AM CDT
Anacor (ANAC) Shares March Higher, Can It Continue?
ANAC: 29.41 (-0.67)
(0)
(0)Anacor Pharmaceuticals (ANAC) Stock Research Links
Scroll down for more posts ▼